Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-08-23
2011-08-23
Young, Shawquia (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S411000, C546S084000, C548S450000
Reexamination Certificate
active
08003661
ABSTRACT:
The invention is directed to naphthalene and quinoline sulfonylurea derivatives as EP4 receptor antagonists useful for the treatment of EP4 mediated diseases or conditions, such as acute and chronic pain, osteoarthritis, rheumatoid arthritis and cancer. Pharmaceutical compositions and methods of use are also included.
REFERENCES:
patent: 2608214 (2006-11-01), None
patent: 02/50032 (2002-06-01), None
Cancer and Metastasis Reviews (1998), 17(1), 91-106.
Science (1999), vol. 286, 531-537.
Cancer [online], [retrieved on Jul. 6, 2007]. Retrieved from the internet, URL http://www.nlm.nih.gov/medlineplus/cancer.html>.
Cancer [online], [retrieved on Jul. 6, 2007]. Retrieved from the internet, URL; http://en.wikipedia.orglwikilCancer.
Burch Jason
Farand Julie
Han Yongxin
Sturino Claudio
Camara Valerie J.
Marucci Maria V.
Merck Canada Inc.
Young Shawquia
LandOfFree
Naphthalene and quinoline sulfonylurea derivatives as EP4... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Naphthalene and quinoline sulfonylurea derivatives as EP4..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Naphthalene and quinoline sulfonylurea derivatives as EP4... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2712617